SPRY · ARS Pharmaceuticals, Inc. · Executive Compensation
$3.11
-0.25 (-7.44%)
At close · Nov 20
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$337.78M
Shares
100.53M
Volume · Nov 20
1.02M
Avg daily vol (3M)
1.81M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Richard Lowenthal | M.S., MSEL President and Chief Executive Officer | $7,174,995 |
| Sarina Tanimoto | M.D., M.B.A. Chief Medical Officer | $4,246,773 |
| Brian T. Dorsey | MSc Chief Operating Officer | $2,235,070 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Richard Lowenthal | M.S., MSEL President and Chief Executive Officer | $10,039,096 |
| Alexander A. Fitzpatrick | Chief Legal Officer and Secretary | $5,318,145 |
| Sarina Tanimoto | M.D., M.B.A. Chief Medical Officer | $4,791,493 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Richard Lowenthal | M.S., MSEL President and Chief Executive Officer | $476,343 |
| Sarina Tanimoto | M.D., M.B.A. Chief Medical Officer | $338,147 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Sarina Tanimoto, M.D. | Chief Medical Officer | Terminated | 2026-07-17 |
| Richard Lowenthal | member of the Board of Directors | Resigned | 2026-07-17 |
| Donn Casale | Class III director | Appointed | 2026-07-07 |
| Donn Casale | Chief Executive Officer | Appointed | 2026-07-07 |
| Donn Casale | President | Appointed | 2026-05-13 |
| Brian T. Dorsey | Chief Operations Officer | Appointed | 2022-12-09 |
| Eric Karas | Chief Commercial Officer | Appointed | 2022-11-08 |
| Dr. Sarina Tanimoto | Chief Medical Officer ("CMO") | Appointed | 2022-11-08 |
| Peter A. Thompson | Class II Director | Appointed | 2022-11-08 |
| Phillip Schneider | Class III Director | Appointed | 2022-11-08 |
| Laura Shawver | Class III Director | Appointed | 2022-11-08 |
| Jonathan S. Leff | Class III Director | Appointed | 2022-11-08 |
| Brenton L. Saunders | Class II Director | Appointed | 2022-11-08 |
| Peter Kolchinsky | Class II Director | Appointed | 2022-11-08 |
| Saqib Islam | Class III Director | Appointed | 2022-11-08 |
| Michael Kelly | Class I Director | Appointed | 2022-11-08 |
| Rajeev Dadoo | Class I Director | Appointed | 2022-11-08 |
| Pratik Shah | Chair of the Board and Class I Director | Appointed | 2022-11-08 |
| Justin Chakma | Chief Business Officer and Secretary | Appointed | 2022-11-08 |
| Eric Karas | Chief Commercial Officer | Appointed | 2022-11-08 |
| Sarina Tanimoto | Chief Medical Officer | Appointed | 2022-11-08 |
| Kathleen Scott | Chief Financial Officer | Appointed | 2022-11-08 |
| Richard Lowenthal | President, Chief Executive Officer and Class II Director | Appointed | 2022-11-08 |
| Jonathan Root | director | Resigned | 2022-11-08 |
| Andrew Powell | director | Resigned | 2022-11-08 |
Leadership
- Donn Casale CEO, Board Member
- Rich Lowenthal CEO
- Richard Lowenthal CEO
- Pratik Shah Chairman
- Kathleen Scott CFO
- Russ Hawkinson CFO
- Brian Dorsey COO
- Brenton L. Saunders Board Member
- Jonathan S. Leff Board Member
- Laura Shawver Board Member
- Michael Kelly Board Member
- Peter A. Thompson Board Member
- Peter Kolchinsky Board Member
- Phillip Schneider Board Member
- Rajeev Dadoo Board Member
- Saqib Islam Board Member
Key facts
CIK
1671858
CUSIP
82835W108
13F (30d)
206 filings
181 filers
Visit website
Investor relations